SPECIAL EMPHASIS PANELS
To view other meetings from ZAI1 choose calendar year:
| Study Section | Panel Name | Meeting Rosters |
|---|---|---|
| ZAI1 PP-A(J1) | CENTERS FOR AIDS RESEARCH (P30 CLINICAL TRIAL NOT ALLOWED); DEVELOPMENTAL CENTERS FOR AIDS RESEARCH (P30 CLINICAL TRIAL NOT ALLOWED) | 12/17/24 |
| ZAI1 JBS-A(J1) | CELL AND GENE THERAPIES FOR HIV CURE: DEVELOPING A PIPELINE (P01 CLINICAL TRIAL NOT ALLOWED) | 12/16/24 |
| ZAI1 AWA-M(M1) | NIAID RESOURCE RELATED RESEARCH PROJECTS (R24 CLINICAL TRIAL NOT ALLOWED) | 12/10/24 |
| ZAI1 SPJ-A(J1) | NIAID RESOURCE-RELATED RESEARCH PROJECTS (R24 CLINICAL TRIAL NOT ALLOWED) | 12/06/24 |
| ZAI1 PT-I(J2) | RESEARCH INITIATIVE FOR VACCINE AND ANTIBIOTIC ALLERGY (UG3/UH3 CLINICAL TRIAL NOT ALLOWED) | 12/05/24 |
| ZAI1 SA-A(J2) | ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH COMMITTEE (AIDS) SPECIAL EMPHASIS PANEL | 12/05/24 |
| ZAI1 MC-D(J1) | NIAID RESEARCH EDUCATION PROGRAM ADVANCING THE CAREERS OF A DIVERSE RESEARCH WORKFORCE (R25 CLINICAL TRIAL NOT ALLOWED) | 12/03/24 |
| ZAI1 RCU-A(J3) | LIMITED INTERACTION TARGETED EPIDEMIOLOGY: EPIDEMIOLOGY OF TRANSMISSION AND TREATMENT OF HIV AMONG PEOPLE WHO ARE AT INCREASED RISK FOR HIV INFECTION IN LATIN AMERICA (LITE-LA) (UG3/UH3 CLINICAL TRIAL OPTIONAL) | 12/03/24 |
| ZAI1 KSW-A(J1) | TAILORING HIV CURATIVE STRATEGIES TO THE PARTICIPANT (UM1 CLINICAL TRIAL NOT ALLOWED) | 12/02/24 |
| ZAI1 RD-W(J1) | INTERNATIONAL RESEARCH IN INFECTIOUS DISEASES (R01 CLINICAL TRIAL NOT ALLOWED) | 12/02/24 |
| ZAI1 MR-I(J2) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 11/26/24 |
| ZAI1 SB-I(J1) | BAT IMMUNOLOGY NETWORK RESEARCH PROJECTS (R01 CLINICAL TRIAL NOT ALLOWED) AND BAT IMMUNOLOGY NETWORK RESEARCH RESOURCE PROGRAM (U24 CLINICAL TRIAL NOT ALLOWED) | 11/25/24 |
| ZAI1 BJM-A(J2) | NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED) | 11/22/24 |
| ZAI1 FDS-M(J1) | FEASIBILITY OF NOVEL DIAGNOSTICS FOR TB IN ENDEMIC COUNTRIES (FEND FOR TB) (R01 - CLINICAL TRIAL NOT ALLOWED) | 11/22/24 |
| ZAI1 VS-A(J2) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 11/21/24 |
| ZAI1 VSR-X(J1) | CENTER OF EXCELLENCE FOR SYSTEMS MODELING OF INFECTION AND IMMUNITY ACROSS BIOLOGICAL SCALES (U54 CLINICAL TRIAL NOT ALLOWED) | 11/21/24 |
| ZAI1 VS-A(J1) | INTERACTION BETWEEN ARVS AND HORMONES IN HIV AND COINFECTIONS (R01 CLINICAL TRIAL OPTIONAL) | 11/19/24 |
| ZAI1 BJM-A(J3) | NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED) | 11/19/24 |
| ZAI1 MS-M(C1) | EVALUATION AND TESTING SERVICES FOR VACCINES AND OTHER BIOLOGICS FOR INFECTIOUS DISEASES (N01) | 11/19/24 |
| ZAI1 JTS-I(J1) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 11/14/24 |
| ZAI1 JTS-I(J2) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 11/14/24 |
| ZAI1 SJ-D(J1) | NIH SUPPORT FOR CONFERENCES AND SCIENTIFIC MEETINGS (PARENT R13 CLINICAL TRIAL NOT ALLOWED) | 11/12/24 |
| ZAI1 MMO-I(J1) | NOVEL APPROACHES FOR RADIATION BIODOSIMETRY ASSAYS AND DEVICES DEVELOPMENT (U01 CLINICAL TRIAL NOT ALLOWED) | 11/12/24 |
| ZAI1 SB-I(J3) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 11/07/24 |
| ZAI1 NKD-D(J1) | SUPPORT FOR RESEARCH EXCELLENCE (SURE) AWARD AND SURE-FIRST INDEPENDENT RESEARCH (SURE-FIRST) AWARD (R16 CLINICAL TRIAL NOT ALLOWED) | 11/07/24 |
| ZAI1 TCB-I(J1) | NIAID SBIR PHASE II CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U44 CLINICAL TRIAL REQUIRED) | 11/07/24 |
| ZAI1 AWA-M(J1) | CENTERS FOR RESEARCH IN EMERGING INFECTIOUS DISEASES (CREID) NETWORK (U01 CLINICAL TRIAL NOT ALLOWED) | 11/06/24 |
| ZAI1 MFH-M(J2) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 11/04/24 |
| ZAI1 MN-M(J3) | CENTERS FOR RESEARCH IN EMERGING INFECTIOUS DISEASES (CREID) NETWORK COORDINATION CENTER (U01 - CLINICAL TRIAL NOT ALLOWED) | 11/04/24 |
| ZAI1 FDS-D(J2) | NIH MEDICAL SCIENTIST PARTNERSHIP PROGRAM (FM1 CLINICAL TRIAL NOT ALLOWED) | 10/31/24 |
| ZAI1 HSC-I(J2) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 10/30/24 |
| ZAI1 RCU-M(J1) | CLINICAL TRIAL PLANNING GRANT (R34); INVESTIGATOR INITIATED EXTENDED CLINICAL TRIAL (R01); CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01); SBIR PHASE II CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U44) | 10/29/24 |
| ZAI1 CAB-M(J1) | CENTERS OF EXCELLENCE FOR TRANSLATIONAL RESEARCH (U19 CLINICAL TRIAL NOT ALLOWED) | 10/29/24 |
| ZAI1 HSC-I(J1) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 10/28/24 |
| ZAI1 BJM-A(J1) | STRATEGIES FOR CONTROLLED RELEASE OF HIV VACCINES (SCORE-H) (R01 CLINICAL TRIAL NOT ALLOWED) | 10/28/24 |
| ZAI1 AM-I(J2) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 10/25/24 |
| ZAI1 RCU-M(J2) | NIAID SBIR PHASE II CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U44 CLINICAL TRIAL REQUIRED) | 10/24/24 |
| ZAI1 SAG-M(J1) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 10/22/24 |
| ZAI1 KLM-I(J1) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 10/18/24 |
| ZAI1 SAG-M(J2) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 10/18/24 |
| ZAI1 MN-M(J2) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 10/15/24 |
| ZAI1 PT-I(J3) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 10/11/24 |
| ZAI1 AM-I(J1) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 10/10/24 |
| ZAI1 PT-I(J1) | NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED) | 10/09/24 |
| ZAI1 SA-M(J1) | NIAID CLINICAL TRIAL PLANNING GRANTS (R34 CLINICAL TRIAL NOT ALLOWED); INVESTIGATOR INITIATED EXTENDED CLINICAL TRIAL (R01 CLINICAL TRIAL REQUIRED); NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED) | 10/01/24 |
| ZAI1 MN-M(J1) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 09/30/24 |
| ZAI1 MFH-M(J1) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 09/20/24 |
| ZAI1 SAS-M(C3) | INTERVENTIONAL AGENTS SAFETY AND PHARMACOKINETIC SERVICES (IASPS) | 09/10/24 |
| ZAI1 SAS-M(C2) | INTERVENTIONAL AGENTS CHEMISTRY SERVICES (IACS) SERVICES, TASK AREA C (N01) | 09/06/24 |
| ZAI1 SA-A(C3) | FUNCTIONAL OMICS CORE LABORATORY (N01) | 08/30/24 |
| ZAI1 SA-A(S2) | NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED) | 08/29/24 |
| ZAI1 MR-I(J1) | NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED) | 08/29/24 |
| ZAI1 VS-A(C1) | HHS-NIH-CDC-SBIR PHS 2022-1 PHASE II: NOVEL PLATFORMS FOR DELIVERY AND/OR EXPRESSION OF HIV ENV IMMUNOGENS FOR HIV VACCINES (TOPIC 101) | 08/20/24 |
| ZAI1 JBS-A(S1) | NIAID RESOURCE RELATED RESEARCH PROJECTS (R24 CLINICAL TRIAL NOT ALLOWED) | 08/12/24 |
| ZAI1 AM-X(S3) | NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED) | 08/12/24 |
| ZAI1 AM-X(S2) | NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED) | 08/08/24 |
| ZAI1 SAS-M(C1) | INTERVENTIONAL AGENTS CHEMISTRY SERVICES (IACS) SERVICES | 08/05/24 |
| ZAI1 LG-M(C1) | DEVELOPMENT OF MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES, RESEARCH AREA 002 ? THERAPEUTIC CANDIDATES (N01) | 07/31/24 |
| ZAI1 RD-D(S2) | NIH SUPPORT FOR CONFERENCES AND SCIENTIFIC MEETINGS (PARENT R13 CLINICAL TRIAL NOT ALLOWED) | 07/29/24 |
| ZAI1 SAS-D(S1) | NIAID RESEARCH EDUCATION PROGRAM ADVANCING THE CAREERS OF A DIVERSE RESEARCH WORKFORCE (R25 CLINICAL TRIAL NOT ALLOWED) | 07/29/24 |
| ZAI1 SJ-M(C3) | VACCINE (AND OTHER BIOLOGIC) MANUFACTURING SERVICES FOR INFECTIOUS DISEASES | 07/26/24 |
| ZAI1 KSW-A(S1) | MULTIDISCIPLINARY RESEARCH TO ACCELERATE HEPATITIS B CURE IN PERSONS LIVING WITH HIV AND HBV (U19 CLINICAL TRIAL NOT ALLOWED) | 07/25/24 |
| ZAI1 MMO-D(S2) | GLOBAL INFECTIOUS DISEASE RESEARCH ADMINISTRATION DEVELOPMENT AWARD FOR LOW-AND MIDDLE-INCOME COUNTRY INSTITUTIONS (G11 CLINICAL TRIAL NOT ALLOWED) | 07/25/24 |
| ZAI1 BJM-A(S1) | HIV VACCINE RESEARCH AND DESIGN (HIVRAD) PROGRAM (P01 CLINICAL TRIAL NOT ALLOWED) | 07/22/24 |
| ZAI1 HSC-I(S1) | DEVELOPMENT OF CANDIDATE RADIATION/NUCLEAR MEDICAL COUNTERMEASURES (MCMS) (U01 CLINICAL TRIAL NOT ALLOWED) | 07/18/24 |
| ZAI1 SPJ-A(S2) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 07/18/24 |
| ZAI1 VSR-X(S1) | OPPORTUNITIES FOR COLLABORATIVE RESEARCH AT THE NIH CLINICAL CENTER (U01CLINICAL TRIAL OPTIONAL) | 07/16/24 |
| ZAI1 JTS-I(S3) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 07/15/24 |
| ZAI1 RK-Z(S2) | STIMULATING ACCESS TO RESEARCH IN RESIDENCY (STARR) (R38 INDEPENDENT CLINICAL TRIAL NOT ALLOWED) | 07/15/24 |
| ZAI1 DF-M(C1) | DEVELOPMENT OF MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES, RESEARCH AREA 001 ? VACCINE CANDIDATES (N01) | 07/15/24 |
| ZAI1 JTS-I(S4) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 07/12/24 |
| ZAI1 JTS-I(S2) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 07/12/24 |
| ZAI1 SAG-A(S1) | INTEGRATED PRECLINICAL/CLINICAL AIDS VACCINE DEVELOPMENT PROGRAM (IPCAVD) (U19 CLINICAL TRIAL NOT ALLOWED) | 07/11/24 |
| ZAI1 SB-I(S2) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 07/09/24 |
| ZAI1 KLM-I(S1) | COMPUTATIONAL MODELS OF INFLUENZA IMMUNITY (U01 CLINICAL TRIAL NOT ALLOWED) | 07/09/24 |
| ZAI1 JTS-I(S1) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 07/09/24 |
| ZAI1 MR-I(S2) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 07/09/24 |
| ZAI1 AM-I(S1) | FC-DEPENDENT MECHANISMS OF ANTIBODY-MEDIATED KILLING (R01 CLINICAL TRIAL NOT ALLOWED) | 07/08/24 |
| ZAI1 VS-A(S1) | PLANNING FOR PRODUCT DEVELOPMENT STRATEGY (R34 CLINICAL TRIAL NOT ALLOWED) | 07/01/24 |
| ZAI1 MC-M(S2) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 06/28/24 |
| ZAI1 SB-I(S1) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 06/28/24 |
| ZAI1 PP-A(S1) | LONG-ACTING DRUG DELIVERY SYSTEMS FOR ART OPTIMIZATION IN CHILDREN LIVING WITH HIV-1 II (LADDS II) (R61/R33 CLINICAL TRIAL NOT ALLOWED) | 06/27/24 |
| ZAI1 MC-M(S1) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 06/27/24 |
| ZAI1 KAR-M(C3) | DEVELOPMENT OF MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES, RESEARCH AREA 003 ? IN VITRO DIAGNOSTICS (N01) | 06/25/24 |
| ZAI1 SA-A(S1) | LIMITED COMPETITION: REVISION APPLICATIONS OF EXISTING NIH CENTERS FOR AIDS RESEARCH (CFAR) AND DEVELOPMENTAL CENTERS FOR AIDS RESEARCH (D-CFAR) GRANTS (P30 CLINICAL TRIAL NOT ALLOWED) | 06/20/24 |
| ZAI1 PT-I(S2) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 06/13/24 |
| ZAI1 RK-M(S1) | RESEARCH TOOLS FOR DIFFICULT TO CULTURE EUKARYOTIC PATHOGENS (R61/R33 CLINICAL TRIAL NOT ALLOWED) | 06/11/24 |
| ZAI1 SPJ-A(S1) | ENGINEERING AND PRECLINICAL DEVELOPMENT OF BIOLOGICAL PRODUCTS THAT ELIMINATE HIV-INFECTED CELLS (UG3/UH3 CLINICAL TRIAL NOT ALLOWED) | 06/07/24 |
| ZAI1 TCB-I(C1) | RNCP PORTFOLIO-WIDE DOSIMETRY VERIFICATION SERVICES | 06/07/24 |
| ZAI1 MR-I(S1) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 06/04/24 |
| ZAI1 PT-I(S1) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 05/24/24 |
| ZAI1 RD-M(S1) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 05/21/24 |
| ZAI1 JTS-I(M3) | NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED) | 05/13/24 |
| ZAI1 LK-A(C2) | HUMORAL IMMUNOLOGY CORE LABORATORY FOR AIDS VACCINE RESEARCH AND DEVELOPMENT (N01) | 05/09/24 |
| ZAI1 CAB-M(S1) | NIAID RESOURCE-RELATED RESEARCH PROJECTS (R24 CLINICAL TRIAL NOT ALLOWED) | 05/08/24 |
| ZAI1 SA-A(C2) | RESOURCE SUPPORT PROGRAM FOR AIDS VACCINE DEVELOPMENT (N01) | 05/06/24 |
| ZAI1 MMO-I(S1) | NIAID CLINICAL TRIAL PLANNING GRANTS (R34 CLINICAL TRIAL NOT ALLOWED) | 05/01/24 |
| ZAI1 MFH-M(S1) | NIAID CLINICAL TRIAL PLANNING GRANTS (R34); NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01); NIAID SBIR PHASE II CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U44); INVESTIGATOR INITIATED EXTENDED CLINICAL TRIAL (R01) | 04/30/24 |
| ZAI1 JTS-I(M2) | NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED) | 04/29/24 |
| ZAI1 KSW-A(M1) | ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH COMMITTEE (AIDS) SPECIAL EMPHASIS PANEL | 04/19/24 |
| ZAI1 FDS-M(M1) | ADVANCING DEVELOPMENT OF DIAGNOSTICS FOR CONGENITAL AND ADULT ACQUIRED SYPHILIS (R21 CLINICAL TRIAL NOT ALLOWED) | 04/18/24 |
| ZAI1 AWA-M(S1) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 04/12/24 |
| ZAI1 VS-A(M1) | NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED) AND INVESTIGATOR INITIATED EXTENDED CLINICAL TRIAL (R01 CLINICAL TRIAL REQUIRED) | 04/12/24 |
| ZAI1 AWA-M(S2) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 04/10/24 |
| ZAI1 MR-I(M2) | NIAID RESOURCE RELATED RESEARCH PROJECTS (R24 CLINICAL TRIAL NOT ALLOWED) | 04/03/24 |
| ZAI1 CAB-D(M1) | NIH SUPPORT FOR CONFERENCES AND SCIENTIFIC MEETINGS (PARENT R13 CLINICAL TRIAL NOT ALLOWED) | 03/26/24 |
| ZAI1 SPJ-D(M1) | SUPPORT FOR RESEARCH EXCELLENCE ? FIRST INDEPENDENT RESEARCH (SURE-FIRST) AWARD (R16 - CLINICAL TRIAL NOT ALLOWED) | 03/21/24 |
| ZAI1 TCB-I(M2) | NIAID CLINICAL TRIAL PLANNING GRANTS (R34 CLINICAL TRIAL NOT ALLOWED) | 03/21/24 |
| ZAI1 RCU-A(M1) | ANALYZING EARLY EVENTS IN TB AND TB/HIV INFECTION FOR INTERVENTIONAL TARGETS (R01 CLINICAL TRIAL NOT ALLOWED) | 03/21/24 |
| ZAI1 PP-A(C2) | VIROLOGY CORE LABORATORY (VCL) | 03/20/24 |
| ZAI1 LG-M(M1) | FUNDAMENTAL RESEARCH TO UNDERSTAND THE MECHANISMS OF NEUROTROPIC VIRUS-MEDIATED DISEASE (R01 CLINICAL TRIAL NOT ALLOWED) | 03/20/24 |
| ZAI1 JTS-I(M1) | ALLERGY, IMMUNOLOGY, AND TRANSPLANTATION RESEARCH COMMITTEE (AITC) SPECIAL EMPHASIS PANEL | 03/18/24 |
| ZAI1 TCB-I(M1) | NIAID CLINICAL TRIAL PLANNING GRANTS (R34 CLINICAL TRIAL NOT ALLOWED) AND INVESTIGATOR INITIATED EXTENDED CLINICAL TRIAL (R01 CLINICAL TRIAL REQUIRED) | 03/14/24 |
| ZAI1 BJM-A(M1) | NIAID RESOURCE RELATED RESEARCH PROJECTS (R24 CLINICAL TRIAL NOT ALLOWED) | 03/11/24 |
| ZAI1 VSR-D(M1) | NIAID NEW INNOVATORS AWARDS (DP2 CLINICAL TRIAL NOT ALLOWED) | 03/11/24 |
| ZAI1 MR-I(M1) | SEX DIFFERENCES IN RADIATION RESEARCH: MODELS, UNDERLYING PATHWAYS, BIOMARKERS OF INJURY, AND MEDICAL COUNTERMEASURE RESPONSES (U01 CLINICAL TRIAL NOT ALLOWED) | 03/11/24 |
| ZAI1 LP-I(M1) | INVESTIGATOR INITIATED EXTENDED CLINICAL TRIAL (R01 CLINICAL TRIAL REQUIRED) | 03/08/24 |
| ZAI1 PT-I(M2) | NIAID SBIR PHASE II CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U44 CLINICAL TRIAL REQUIRED) | 03/07/24 |
| ZAI1 SB-X(M1) | DEVELOPMENT OF SOFTWARE FOR DATA SCIENCE IN INFECTIOUS AND IMMUNE-MEDIATED DISEASES RESEARCH (U01 CLINICAL TRIAL NOT ALLOWED) | 03/06/24 |
| ZAI1 AWA-M(M2) | NIAID SBIR PHASE II CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U44 CLINICAL TRIAL REQUIRED), CLINICAL TRIAL PLANNING GRANT (R34 CLINICAL TRIAL NOT ALLOWED), CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL | 03/06/24 |
| ZAI1 SAS-M(M2) | NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED); INVESTIGATOR INITIATED EXTENDED CLINICAL TRIAL (R01 CLINICAL TRIAL REQUIRED) | 03/06/24 |
| ZAI1 SA-A(C1) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I: DEVELOPMENT OF LONG-ACTING TREATMENTS FOR HCV CURE (TOPIC 125) | 03/01/24 |
| ZAI1 SAS-M(M1) | NIAID SBIR PHASE II CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U44 CLINICAL TRIAL REQUIRED); NIAID CLINICAL TRIAL PLANNING GRANTS (R34 CLINICAL TRIAL NOT ALLOWED); NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT | 02/29/24 |
| ZAI1 AWA-M(M1) | NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED); NIAID SBIR PHASE II CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U44 CLINICAL TRIAL REQUIRED); CLINICAL TRIAL PLANNING GRANTS (R34 CLINICAL TRI | 02/29/24 |
| ZAI1 DF-M(M1) | ANIMAL MODELS FOR HEPATITIS B AND C (R01 CLINICAL TRIAL NOT ALLOWED) | 02/29/24 |
| ZAI1 MR-I(M3) | PAR-23-065, NIAID RESOURCE RELATED RESEARCH PROJECTS (R24 CLINICAL TRIAL NOT ALLOWED) | 02/29/24 |
| ZAI1 HSC-X(M1) | IMMUNE MECHANISMS AT THE MATERNAL-FETAL INTERFACE (R01 CLINICAL TRIAL NOT ALLOWED) | 02/28/24 |
| ZAI1 NKD-M(C2) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I: SOFTWARE OR WEB SERVICES TO RE-REPRESENT EXISTING SCIENTIFIC DATA AND KNOWLEDGE INTO A KNOWLEDGE GRAPH FORMAT (TOPIC 136) | 02/27/24 |
| ZAI1 PT-I(M1) | NIAID CLINICAL TRIAL IMPLEMENTATION COOPERATIVE AGREEMENT (U01 CLINICAL TRIAL REQUIRED) | 02/27/24 |
| ZAI1 BJM-A(C1) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I: DEVELOPMENT OF NOVEL IN-VITRO AND IN-VIVO MODELS TO SUPPORT NEUROHIV RESEARCH (TOPIC 002) | 02/27/24 |
| ZAI1 PT-I(C1) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I AND PHASE II: REAGENTS FOR IMMUNOLOGIC ANALYSIS OF NON-MAMMALIAN AND UNDERREPRESENTED MAMMALIAN MODELS (TOPIC 129) | 02/26/24 |
| ZAI1 SPJ-A(C2) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I: POINT-OF-CARE HIV VIRAL LOAD AND DRUG ADHERENCE ASSAYS (TOPIC 001) | 02/26/24 |
| ZAI1 JTS-I(C1) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I AND PHASE II: ADJUVANT DISCOVERY AND DOWN-SELECTION FOR VACCINES AGAINST INFECTIOUS AND IMMUNE-MEDIATED DISEASES (TOPIC 130) | 02/23/24 |
| ZAI1 PP-A(C1) | HHS-NIH-SBIR PHS 2024-1 PHASE I/II: DEVELOPMENT OF NEXT-GEN DEVICES AND MATERIALS-BASED PLATFORMS FOR THE ADMIN OF HIV-1 BNABS (TOPIC 124); PHS 2020-1 PHASE II: PARTICLE-BASED CO-DELIVERY OF HIV IMMUNOGENS AS NEXT-GEN VACCINES (TOPIC 77) | 02/22/24 |
| ZAI1 LK-A(C1) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I: RAPID DIAGNOSTIC ASSAYS FOR SELF-MONITORING OF ACUTE OR REBOUND HIV-1 INFECTION (TOPIC 126) | 02/22/24 |
| ZAI1 SPJ-A(C1) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I: SOFTWARE OR WEB SERVICES TO AUTOMATE METADATA ENRICHMENT AND STANDARDIZATION FOR DATA ON INFECTIOUS AND IMMUNE ? MEDIATED DISEASES (TOPIC 135) | 02/21/24 |
| ZAI1 SJ-M(C2) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I: DEVELOPMENT OF BACTERIOPHAGE FOR TREATMENT OF MYCOBACTERIAL INFECTIONS (TOPIC 131) | 02/21/24 |
| ZAI1 MN-M(C1) | SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE II PROGRAM CONTRACT SOLICITATION (PHS 2022-1) TOPIC 108 - DEVELOPMENT OF RAPID POC DIAGNOSTICS FOR TREPONEMA PALLIDUM (N01) | 02/16/24 |
| ZAI1 MN-M(C2) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I: NOVEL DIAGNOSTIC BIOMARKER DISCOVERY AND VALIDATION FOR MALARIA AND SELECT NEGLECTED TROPICAL DISEASES (NTDS) (TOPIC 132) | 02/15/24 |
| ZAI1 SAG-A(C1) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I/II: MULTIPLEXED PATIENT ADMINISTERED DIAGNOSTICS FOR HEPATITIS B, HEPATITIS C, AND HIV (TOPIC 127) | 02/15/24 |
| ZAI1 SJ-M(C1) | SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE II PROGRAM CONTRACT SOLICITATION (PHS 2022-1) TOPIC 112 - DIGITAL TOOLS AGAINST MISINFORMATION ABOUT INFECTIOUS DISEASE TREATMENTS AND VACCINES (N01) | 02/14/24 |
| ZAI1 KAR-M(C2) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I: ALTERNATIVES TO BENZATHINE PENICILLIN FOR TREATMENT OF SYPHILIS (TOPIC 134) | 02/12/24 |
| ZAI1 MMO-I(C1) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I: ADJUVANT DEVELOPMENT FOR VACCINES FOR INFECTIOUS AND IMMUNE-MEDIATED DISEASES (TOPIC 128) | 02/08/24 |
| ZAI1 KJK-I(C1) | NIAID SPF MACAQUE BREEDING COLONIES | 02/07/24 |
| ZAI1 KAR-M(C1) | HHS-NIH-CDC-SBIR PHS 2024-1 PHASE I: DEVELOPMENT OF A SEROLOGICAL TEST FOR HERPES SIMPLEX TYPES 1 AND 2 INFECTIONS (TOPIC 133) | 02/06/24 |
| ZAI1 NKD-M(C1) | SMALL BUSINESS INNOVATION RESEARCH (SBIR) PHASE II PROGRAM CONTRACT SOLICITATION (PHS 2022-1) TOPIC 109 - DEVELOPMENT OF MONOCLONAL ANTIBODY-MEDIATED INTERVENTIONS TO COMBAT MALARIA (N01) | 02/06/24 |
| ZAI1 RK-M(M1) | BIOINFORMATICS RESOURCE CENTERS (BRCS) FOR INFECTIOUS DISEASES (U24 CLINICAL TRIAL NOT ALLOWED) | 01/31/24 |
| ZAI1 RCU-A(J1) | PA20-186, MIDCAREER INVESTIGATOR AWARD IN PATIENT-ORIENTED RESEARCH (PARENT K24 INDEPENDENT CLINICAL TRIAL NOT ALLOWED) | 01/24/24 |
| ZAI1 LP-I(C1) | INNOVATIONS IN FUNCTIONAL B CELL EPITOPE DISCOVERY (N01) | 01/18/24 |
| ZAI1 SA-A(J2) | NIAID INVESTIGATOR INITIATED PROGRAM PROJECT APPLICATIONS (P01 CLINICAL TRIAL NOT ALLOWED) | 01/09/24 |